[Effectiveness of various alfuzosin schedules in patients with benign prostatic hyperplasia (BPH)].
238 patients with initial BPH (mean age 64.07 years) were treated with alfusosine in a standard dose 5 mg twice a day for 6 months. After that 117 patients continued the above scheme while 121 patients continued to receive alfusosine in the same dose each other day. The results assessed by IPSS, QOL, maximal urine flow rate, levels of prostate-specific antigen in the serum appeared identical in both groups. Thus, the split course of alfusosine after 6-month standard therapy is perspective as it is more cost effective than the standard scheme being equally beneficial.
O B
OB
Loran
P I
PI
Rasner
D
D
Kosko
D Iu
DIu
Pushkar'
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D011799:Quinazolines / Q000627:therapeutic use*; D014563:Urodynamics / Q000187:drug effects
D000317:Adrenergic alpha-Antagonists; D015415:Biomarkers; D011799:Quinazolines; C047638:alfuzosin; D017430:Prostate-Specific Antigen